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Immunotherapies are revolutionizing the clinical management of a wide range of cancers. However, in-
trinsic or acquired unresponsiveness to immunotherapies does occur due to the dynamic cancer immu-
noediting which ultimately leads to immune escape. The evolutionarily conserved histone modifier en-
hancer of zeste 2 (EZH2) is aberrantly overexpressed in a number of human cancers. Accumulating studies
indicate that EZH2 is a main driver of cancer cells’ immunoediting and mediate immune escape through
downregulating immune recognition and activation, upregulating immune checkpoints and creating an
immunosuppressive tumor microenvironment. In this review, we overviewed the roles of EZH2 in can-
cer immunoediting, the preclinical and clinical studies of current pharmacologic EZH2 inhibitors and the
prospects for EZH2 inhibitor and immunotherapy combination for cancer treatment.
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The emerging role of immune therapies in cancer
Drugs that enhance the patient’s immune response against malignant cells are generically called ‘cancer immunother-
apies’. These treatments are rapidly emerging as an effective therapeutic option for several solid tumors, most notably
advanced melanoma, non-small-cell lung cancer, renal cell carcinoma and bladder cancer [1]. In these and other ma-
lignancies, immunotherapies display remarkable response rates and significantly improve patient survival. However,
other common solid tumors (breast, prostate, colon) seem to be less susceptible to cancer immunotherapies. Even
within the more ‘immune-susceptible’ cancers, oncologists have observed substantial inter-patient differences, with
some exceptional responders and some intrinsically refractory patients. Finally, in some cases immunotherapies
induce short-lived responses, which are followed by a rapid tumor progression [2,3]. All these clinical observations
suggest that cancer cells and their microenvironment trigger molecular mechanisms that reduce or completely
abrogate the efficacy of immunotherapies. Of note, the immune-resistant mechanisms in cancer immunotherapy
overlap with the immunoediting process used by cancers to evade immunosurveillance, such as reduced antigenicity
and immunogenicity, failure to recruit immune effector cells and decreased antitumor effector function caused by
various immune checkpoints and suppressive tumor microenvironment [2–5].
In addition to DNA mutations, epigenetic alterations have been recently identified as driver of immunoediting
and resistance to cancer immunotherapies. Epigenetic modifications are defined as heritable phenotypic changes
that are not due to changes in DNA primary structure [6]. Unlike genetic mutations, epigenetic alterations are
reversible and are targetable by clinically approved drugs. Hence, these alterations offer a unique possibility to
modulate the gene expression profile of the tumor, in order to make it more susceptible to immunotherapies and
to prevent the emergence of resistant clones. One particular epigenetic effector enhancer of zeste 2 (EZH2) is
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more and more recognized as a main driver of cancer cells’ immunoediting and mediates immune escape through
downregulating immune recognition and activation, upregulating immune checkpoints and creating an immuno-
suppressive tumor microenvironment [7–10]. In this review, we will focus on the mechanisms of immunotherapy
and immunotherapy resistance, the role of EZH2 in immunoediting and the potential of using EZH2 inhibitor to
overcome immunotherapy resistance.
The interaction between cancer & the immune system
Cancer remains one of the leading causes of death in the world. According to the immunosurveillance theory,
cancer initiation and development are constantly monitored and restrained by the immune system [11,12]. Cytotoxic
effector cells play key roles in mediating cancer surveillance and elimination. In particular, CD8+ cytotoxic T
lymphocytes (CTLs) are considered the most prominent tumoricidal effector cells. Upon priming and activation
by antigen-presenting cells, CTLs can perform potent and tumor-specific killing in a MHC class I-restricted
manner [13]. Besides, innate cytotoxic effector cells, such as natural killer (NK) cells, γδ T cells and tissue residing
macrophages, are able to display rapid cytolytic activity in response to transformed cells [14–16]. Apart from the
aforementioned cytotoxic effector cells, CD4+ T helper 1 (Th1) cells have a crucial role in anti-tumor immunity:
Th1 cells provide critical assistance in the priming, activation and cytotoxicity of CTLs [17]; Th1 cytokines can
promote the tumoricidal activity of macrophages and NK cells [18].
Theoretically, cancer development and outgrowth can be inhibited by cytotoxic innate and adaptive immune
cells. However, despite the existence of a normal host immune system, many cancers manage to persist and progress.
During this process, cancer cells evolve different mechanisms to avoid tumoricidal attack by negatively shaping
anti-tumor immune responses [19,20].
Immune selection, immune editing & immune escape
Although cancer originates from a single transformed cell, it eventually develops into a heterogeneous population
with various phenotypes due to genetic instability and epigenetic plasticity. When effective immunosurveillance
posts a selection pressure on this heterogeneous population, some cancer clones are killed whereas other clones
that are unsusceptible or resistant to antitumor immune responses are selected and maintained. Therefore, cancer
development is considered as a Darwinian evolutionary process where the immune response is able to drive the
cancer evolution toward an immune-resistant phenotype [21–24]. Particularly, it has been proposed that surviving
epithelial cancers may acquire immune-suppressive preparties via a transdifferentiation process of ‘epithelial immune
cell-like transition’, which enables the cancer cells to ‘communicate’ with immune cells [25]. Hence, the host immune
system can both constrain and promote cancer development through the process of ‘cancer immunoediting’ [5,26].
Cancer immunoediting includes three sequential phases (‘three Es’, Figure 1), elimination, equilibrium and
escape [4]. During these three phases, cancer gradually acquires active immune suppressive functions through
reducing antigenicity (loss of neoantigens and/or poor antigen presentation), decreasing immunogenicity (failure
to recruit and/or activate effector cells) and creating an immunosuppressive tumor microenvironment (TME) [27].
At the elimination phase, cancer cells can be effectively removed by immune effector cells. When certain variants
survive but remain quiescent/dormant, cancer progresses into the equilibrium phase. At the equilibrium phase,
cancer variants manage to avoid elimination mostly through reducing antigenicity [28,29]. Cancer then gradually
shifts to the escape phase when more complicated immune evading phenotypes are acquired. First, cancer can further
reduce neoantigen expression and acquire deficiencies in antigen presentation by loss of MHC I (human leukocyte
antigen A, B and C, HLA-A, -B and -C) expression or dysregulation of antigen processing machinery [30,31]. By
doing so, cancer cells can avoid the recognition and cytotoxic effect of T cells. Besides, some cancer can upregulate
nonclassical HLA molecules (such as HLA-E and HLA-G), which are usually expressed at immune-privileged sites,
to limit NK reactivity upon interaction with inhibitory receptors [31–33]. Second, cancer can upregulate co-inhibitory
receptors/ligands to limit anti-cancer activity. Among them, programmed cell death protein 1 (PD-1), PD-1
ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) are potent immune checkpoints
involving in the negative regulation of T-cell reactivity [34,35]. Besides, a growing list of other co-inhibitory
receptors, including T-cell immunoreceptor with Ig and ITIM domains (TIGIT), T-cell immunoglobulin and
mucin domain-containing protein 3 (TIM-3) and Lymphocyte-activation gene 3 (LAG-3), also play important
roles in undermining T- and NK-cell responses [36–38]. Third, cancer is able to create an immunosuppressive TME
flooded with immunosuppressive factors and immunosuppressive cells. The immunosuppressive factors include
cytokines such as IL-4, IL-10, IL-13, IL-23 and TGF-β [39], as well as metabolites such as indoleamine 2,3-
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Figure 1. Schematic representation of the ‘3E’ theory. Cancer immunoediting includes three sequential phases:
elimination, equilibrium and escape. At the elimination phase, antigenic cancer cells can be effectively removed by
immune effector cells. At the equilibrium phase, some cancer cells which have a nonimmunogenic phenotype manage
to evade the immune elimination and survive. As such, a balance is established between cancer and the immune
system. At the escape phase, cancer evades the immune response through more complicated mechanisms, such as
downregulating antigenicity, upregulating immune inhibitory molecules and generating an immunosuppressive TME
flooded with suppressive cells and factors. Cancer manages to grow in an uncontrolled manner. In the whole process
of immunoediting, the accumulation of epigenetic alterations leads to profound changes in tumor cells and tumor
microenvironment that contribute to decreased antitumor immunity and tumor immune escape.
dioxygenase-1 (IDO) [40] and lactic acid [41,42]. The immunosuppressive cells, including Tregs, myeloid-derived
suppressor cells (MDSCs) and tumor-associated macrophages (TAMs, M2 macrophages), are capable of repressing
effector activity and are either induced in situ or newly recruited and settled to the suppressive TME [43]. Gradually,
the immune system becomes incompetent to suppress cancer growth. Cancer successfully escapes and progresses
into clinical overt cancer.
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The emerging role of immunotherapies: restoring immunosurveillance & counteracting immune
escape mechanisms
Nowadays, escape from immunosurveillance is increasingly recognized as a hallmark event in cancer initiation
and progression. Immunotherapies aiming at restoring immunosurveillance and counteracting immune escape
mechanisms are revolutionizing the clinical management of a wide range of cancers [20,27].
The most straightforward way to restore cancer immunity is by increasing the number of effector cells. Anti-
cancer effector cells can either be activated and expanded in vivo through cancer vaccine immunization or be
expanded and manipulated in vitro and then transferred to cancer patients as seen in adoptive cell therapy and
engineered chimeric antigen receptor (CAR)-T cell therapy [44,45]. Besides, antibody-based targeting therapeutics
are able to recruit effector cells to the tumor site [46]. For cancer types that exclude efficient immune cell infiltration
(immunologically cold), a series of targeted therapies can be used to reprogram the TME and make it more
permissive to effector cells. These therapies include: Toll-like receptor (TLR) agonists [47,48], VEGF neutralizing
antibodies [49], signal transducer and activator of transcription 3 (STAT3) inhibitors [50,51], Wnt/β-catenin pathway
inhibitors [52] and stimulator of interferon genes agonists [2,53,54]. Some of these therapies are currently approved
for the treatment of specific malignancies. For example, the anti-VEGF antibody bevacizumab is employed for the
treatment of metastatic renal, colorectal and ovarian cancer and for recurrent gliomas [55]. Other targeted therapies
are being tested in Phase I/II clinical trials [56].
Another effective strategy that enhances the antitumor immune response is to counteract immune inhibitory
mechanisms. Co-inhibitory receptors (particularly immune checkpoint receptors) upregulated on effector T and
NK cells can dampen anti-cancer responses. Accordingly, immune checkpoint blockade (ICB) therapies targeting
PD-1 and CTLA-4 have demonstrated clinical efficacy in a variety of solid tumors and are now the standard
treatment for advanced melanoma and non-small cell lung carcinoma (NSCLC) [57,58]. In addition, antibodies that
block other co-inhibitory receptors such as TIGIT, TIM-3 and LAG-3, either alone or in combination with ICB,
have also shown satisfactory efficacies in mouse models and are now being tested in Phase I/2/3 clinical trials for
the treatment of melanoma, renal cell carcinoma, NSCLC and other solid tumors [2,43,59–61].
Apart from co-inhibitory receptors, the anticancer activity of effector cells is also strongly inhibited by the
immunosuppressive TME. Various antagonists that block the action of immunosuppressive cytokines (e.g., IL-
23 [62,63] and TGF-β [64,65]) and metabolites (e.g., IDO [40]) have been shown to effectively prevent the induction
and enrichment of the suppressive cells in TME in preclinical studies. Among them TGF-β and IDO antagonists,
either alone or in combination with ICB, chemotherapy or radiotherapy, are being tested in Phase I/II trials for the
treatment of patients with solid tumors [40,66]. In addition, the depletion or reprogramming of TME suppressive
cells (e.g., Tregs [67,68], myeloid-derived suppressor cells [69,70] and M2-TAMs [71,72]) have been reported to enhance
anticancer immune responses in both preclinical and clinical settings.
Of interest, cancer prefers aerobic glycolysis over the more energy-efficient oxidative phosphorylation pathway, a
property known as the ‘Warburg effect’ [73,74]. This altered metabolism results in the accumulation of lactic acid and
consequent acidification of TME. Notably, the acidic TME has been linked to multiple mechanisms of immune
suppression and become an attractive target for cancer immunotherapy [41,75,76]. Blocking lactic acid transportation
through monocarboxylate transporter 1 (MCT 1) and/or 4 (MCT 4) have been shown to inhibit tumor growth
in preclinical studies [75,77,78]. Moreover, MCT1 inhibitor AZD3965 is currently being tested in a Phase I trial for
the treatment of patients with small-cell lung carcinoma [79].
Considering the complexity and diversity of the immune context of the TME, the response rate to certain
immunotherapies may differ substantially between cancer patients. For this reason, Binnewies et al. have stratified
tumor immune microenvironment into three classes according to the composition of the immune infiltrate and
the character of the inflammatory response [43]. Similarly, O’Donnell et al. have proposed a four-type TME
stratification model, which also takes tumor mutational burden into consideration, along with tumor inflammatory
gene signature [2]. Although both models are valuable in predicting clinical responsiveness and guiding the proper
selection of immunotherapeutic strategies, given the fact that altered metabolism (particularly elevated lactic
acid production) in TME can cause general immune suppression and dampen the clinical efficacy of cancer
immunotherapies [41,80], it is important to also consider the metabolic signature of TME in this respect.
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Epigenetic immune editing: an early mechanism of therapy resistance
Intrinsic & acquired resistance to immunotherapy
As discussed above, owing to the complex immunoediting and immune escape mechanisms, some cancers can
be effectively controlled by immunotherapies, whereas others are intrinsically unresponsive or resistant to it.
Significantly, even for those cancers that respond well to immunotherapy, the responses may be transient due to
potent acquired resistance mechanisms [81–84]. For example, intrinsic ICB resistance is most likely due to low tumor
mutational burden and/or poor immune cell infiltration which leads to minimal immune recovery with both
CTLA-4 and PD-1/PD-L1 blockade [85–87]. Whereas acquired ICB resistance has been linked to more complex
mechanisms of adaptation, like loss of neoantigen, poor antigen presentation, failure to recruit and activate T cells
and upregulation of alternative immune checkpoints [88–92].
Of note, immunoediting used by cancer to evade immunosurveillance also occurs in cancer undergoing im-
munotherapy. While effective immunotherapy can suppress cancer progression, it may also lead to immunoselection
and outgrowth of resistant cell clones. Thus, to fully eradicate a clinically overt cancer, it is necessary to effectively
disrupt the evolutionary processes leading to cancer cell adaptation and therapeutic resistance.
The role of epigenetics in immunoediting
Intratumoral heterogeneity is a necessary precondition for cancer progression and for immunoselection. Emerging
evidence suggests that epigenetic modifications are key mediators of cancer heterogeneity [93]. It has been suggested
that epigenetic modifications often precede genetic alterations and that these reversible alterations confer lineage
plasticity to cancer cells [94]. Epigenetic mechanisms include DNA methylation and histones post translational
modifications. Histones are basic proteins that compact the DNA into structural units known as nucleosomes.
Each nucleosome is composed of an octamer containing two copies of each core histone (H2A, H2B, H3 and
H4). Approximately 147 bp of DNA are wrapped around each nucleosome. Each core histone contains a long
N-terminal tail, which can be modified by a number of post translational modifications (acetylation, methylation,
phosphorylation) [95]. While DNA methylation of promoters is associated with gene silencing, histones post
translational modifications can enhance or suppress local gene expression, depending on the histone residue
affected and on the nature of the chemical modification. For example, histone acetylation favors a transcriptionally
active chromatin structure and is therefore associated with active gene expression. These modifications are able to
affect the genomic structure and regulate gene expression without affecting the DNA sequence [96].
Aberrant epigenetic modifications are widely described as essential players in cancer immunoediting and immune
escape [97–99]. For example, it has been shown that the loss of HLA and the depletion of expressed neoantigens are
due to increased DNA methylation and reduced histone acetylation [23,29]. In addition, DNA hypomethylation
and increased histone acetylation status of the CTLA-4, PD-1 and PD-L1 promoter regions have been shown to
be associated with the upregulation of these genes in the TME [100–102]. Moreover, growing evidence suggests that
cancer can shape the immune landscape of TME through changing the epigenetic modification portfolio of relevant
genes. Thereby, a suppressive cytokine environment can be established and suppressive cellular components can be
induced and recruited [90,103–107].
Unlike genetic alterations, epigenetic alterations can be reversed pharmacologically [108]. Notably, epigenetic
modifiers, like inhibitors of DNA methyltransferase or histone deacetylase was shown to be able to synergize with
immunotherapy for the eradication of mouse tumor models [109–111]. Moreover, epigenetic therapy in combination
with ICB therapy was proven to produce longer periods of disease-free survival and increased overall survival in
NSCLC patients [112]. Therefore, epigenetic therapies have the potential to reprogram the immunosurveillance-
and immunotherapy-driven cancer evolution. When combined, epigenetic therapy may potentiate current im-
munotherapy to maximize benefits and overcome acquired therapy resistance.
EZH2 functions in immune editing
Emerging evidence indicates that several of the aforementioned mechanisms of epigenetic editing are mediated
by the evolutionarily conserved histone modifier EZH2. The EZH2 locus encodes the catalytic subunit of the
polycomb repressive complex 2 (PRC2), a multimeric complex that mediates gene silencing via histone H3 lysine
27 trimethylation (H3K27me3) [113]. Other PRC2 components include SUZ12 (suppressor of zeste 12) and EED
(embryonic ectoderm development), which stabilize the complex and promote the dissemination of the H3K27me3
to nearby nucleosomes (Figure 2). Gene duplication in higher vertebrates has generated the EZH1 locus, which
encodes another methyl-transferase with partially redundant functions [114]. Protein sequence alinement revealed
future science group 10.2217/epi-2020-0186








Gene silencing Gene activation
Figure 2. Canonical (left) and non-canonical (right) EZH2 mechanisms of action. The canonical mechanism of action
of EZH2 involves gene silencing via H3K27 tri-methylation. In this case, EZH2 acts as the catalytic subunit of polycomb
repressive complex 2 (which includes SUZ12 and EED). Emerging evidence indicates that EZH2 can also act via
PRC2-independent mechanisms. These noncanonical mechanisms of action include the methylation and activation of
some transcription factors.
that EZH2 and EZH1 are highly conserved in vertebrates and that these proteins are the only enzymes capable of
catalysing the H3K27me3 modification. It is still not clear to which extent EZH1 and EZH2 functions differ in
physiological conditions. Notably, the gene silencing activity of PRC2 can be directed to specific loci by interactions
with long noncoding RNAs (lncRNAs), such as HOTAIR and NEAT1 [115]. In addition to the PRC2-dependent gene
silencing, several non-canonical functions of EZH2 have been recently identified. These include gene silencing via
H3K9me3 [116,117], the activation of the transcription factors STAT3 [118] and NFKB [119]. Hence, EZH2 functions
include both gene repression and activation and seem to be highly dependent on the local interaction with other
macromolecules.
PRC2 proteins regulate the self-renewal of embryonic and hematopoietic stem cells [120] and the correct devel-
opment of the immune systems [121]. PRC2 target genes are highly dependent on the cellular context; for example,
in embryonic stem cells PRC2 silences the expression of cell cycle inhibitors and lineage-specific genes [120]; in lym-
phoid cells PRC2 controls the timely expression of cytokines and other factors that regulate the correct maturation
and activation of B and T cells [121].
The importance of PRC2 proteins in embryo development is confirmed by the observation that homozygous
mutations in any of the PRC2 components cause early embryonic lethality in mice [122]. In humans, congenital
heterozygous mutations of EZH2 cause a wide spectrum of pathologic phenotypes, ranging from tall stature without
intellectual disability to typical Weaver syndrome (tall stature, facial dysmorphia and intellectual disability) [123].
Beyond its physiological functions, EZH2 has been shown to regulate the activity of cancer cells. EZH2
overexpression has been identified in a wide variety of solid malignancies, including breast, prostate and lung
cancers [113]. Notably, EZH2 over-expression is almost invariably associated with worse prognosis in different
cancers [124,125]. Mechanistically, EZH2 controls the coordinated inactivation of several tumor suppressor genes,
thereby promoting cancer growth, metastasis and drug resistance [126,127]. Moreover, EZH2 expression in the TME
can indirectly promote cancer progression. For example, EZH2 has been shown to stimulate the production of
pro-angiogenic factors by tumor associated fibroblasts [128]. Considering the pro-oncogenic roles of EZH2 in both
cancer cells and tumor-associated cells, it is not surprising that a variety of EZH2 inhibitors are being tested in
cancer clinical trials (as discussed in the next section). It is interesting to note that, even though EZH1 has partially
redundant physiological functions, the oncogenic role of this gene is much less investigated. However, some reports
suggest that EZH1 cooperates with EZH2 to drive a malignant phenotype [129]. As will be discussed in the next
section, most of the currently available PRC2 inhibitors preferentially target EZH2. Hence, EZH1 overexpression
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Figure 3. EZH2 regulates several aspects of the adaptive and innate antitumor immune response. (A) Intratumoral
EZH2 expression suppresses the adaptive antitumor immune response. EZH2 expression in cancer cells inhibits T-cell
activation by suppressing the MHC-I antigen presentation pathway and upregulating PD-L1 expression. Besides cancer
cells, EZH2 expression in Treg cells is crucial for maintaining their regulatory phenotype and function, which also
results in reduced T-cell activation. (B) Intratumoral EZH2 expression suppresses the innate antitumor immune
response. EZH2 expression in cancer cells silences the expression of NKG2D ligands, thereby blocking the activation of
NK cells and favors the secretion of CCL5, which recruits immunosuppressive M2-type macrophages to TME. Besides
cancer cells, EZH2 expression in NK cells directly inhibits their maturation, activation and antitumor activity.
NK: Natural killer.
could be a mechanism of intrinsic or acquired resistance to these drugs. It will be therefore important to test dual
EZH1/EZH2 inhibitors for cancer treatment [130].
The recent success of cancer immune therapies has attracted attention on a less investigated feature of PRC2,
in other words, its ability to regulate the relationship between cancer and the immune system. To understand the
complex roles of PRC2 in these contexts, we must bear in mind that the functions of most epigenetic effectors are
cell specific. For this reason, we will discuss the immune-editing functions of PRC2 in the context of the adaptive
and innate immune response.
EZH2 suppresses the activation of the adaptive immune response
A growing body of evidence indicates that, in addition to its oncogenic functions, intratumoral EZH2 expression
inhibits the adaptive immune response (Figure 3A). One of the main mechanisms of cancer immune evasion
is the suppression of the MHC-I antigen processing pathway (MHC-APP). A recent genome-wide functional
screening revealed that PRC2 genes are essential for promoting the coordinated silencing of MHC-APP genes
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in both leukemia and solid cancer cells [7]. The study showed that increased H3K27me3 at MHC-APP loci had
a double effect: it reduced the basal expression of these genes; it inhibited the activation of these genes, which
is normally induced by IFN-γ. These mechanisms of epigenetic repression are essential for evading the immune
surveillance of effector T cells. Upon analysis of a wide range of cancer cell lines, the authors of this study found
that neuroendocrine cancers show the lowest expression of MHC-APP proteins and the highest expression of
PRC2 genes. Interestingly neuroendocrine trans-differentiation is emerging as a common mechanism of resistance
to targeted therapies in prostate and lung cancers [131]. We have shown that PRC2 genes drive neuroendocrine
trans-differentiation in prostate cancer [132]. Hence it is conceivable that the ability to evade the immune response
is one of the microevolutionary pressures driving the PRC2-dependent neuroendocrine trans-differentiation.
Another mechanism by which cancer cells inhibit the T cell-mediated immune response is the upregulation of the
immune checkpoint protein PD-L1. In lung cancer cells, EZH2 promotes the expression of PD-L1 by activating
the hypoxia-inducible factor 1α [133]. A clinical study on resected lung adenocarcinomas confirmed the positive
correlation between EZH2 and PD-L1 expression [8]. However, an opposite correlation between these two genes
has been identified in hepatocellular carcinoma. In this case, EZH2 directly induces H3K27me3 at the promoter of
PD-L1, thereby triggering gene silencing [134]. These results highlight the cell-specificity of PRC2 proteins, which
will need to be considered in future translational studies.
In addition, EZH2 controls the adaptive response via regulation of Treg activity. As discussed, Tregs are a subtype
of T cells that induce immunotolerance toward cancer cells. In particular, Treg cells produce a range of cytokines
that suppress the activation and recruitment of both cytotoxic (CD8+) and helper (CD4+) T effector T cells.
It has been shown that EZH2 is essential for the maintenance of the Treg phenotype. EZH2 inhibition in Treg
cells leads to the recruitment of CD4+ and CD8+ effector T cells, which elicit a potent antitumor response [9].
Hence, EZH2 expression in both cancer cells and tumor-infiltrating T cells seem to elicit an immune-tolerant
phenotype and to promote cancer progression, thus positioning EZH2 inhibitors as attractive potential adjuvants
for immunotherapy.
EZH2 controls the phenotype of TAMs & NKs
Intratumoral EZH2 expression has also been shown to control the innate immunity (Figure 3B). NKs are lympho-
cytes that recognize and kill cancer cells in an antigen-independent manner [135]. NKs express activating NKG2D
receptors on their surface. When an NKG2D receptor binds its ligand, which can be expressed in cancer cells,
NKs initiate a cytotoxic immune response. Cancer cells expressing EZH2 can suppress the expression of NKG2D
ligands, thereby escaping the NK cytotoxic response [136]. Notably, EZH2 can also be expressed by NK cells. In this
case, EZH2 directly inhibits NK differentiation and activation [137], hence EZH2 inhibition could have a double
positive impact in eliciting a NK-mediated immune response against cancers.
Another important component of the TME is represented by TAMs. Two main types of TAMs have been
described in the TME: M1-TAMs are characterized by the expression of inflammatory cytokines and by cytotoxic
capabilities; M2-TAMs express anti-inflammatory mediators and tend to reduce the local immune response, thereby
favoring cancer progression. Hence, cancer cells tend to recruit M2-TAMs in the TME. EZH2 has been implicated
also in this phenomenon. For example, EZH2 expression in lung cancer cells increases the secretion of the chemokine
CCL5, which triggers the recruitment of TAMs [10]. This process promotes invasion and metastasis. In gliomas,
EZH2 expression shifts macrophages and microglia from M1 to M2 phenotype, thereby reducing the anticancer
immune response [138].
In addition to these mechanisms of direct immune response inhibition, EZH2 has been also implicated in
cancer metabolic reprogramming. For example, in glioblastomas EZH2 favors the production of lactic acid via
the Warburg effect [139]. As discussed in the previous paragraphs, the creation of an acidic TME is a generalized
mechanism of immune suppression. Taken together, these results indicate that intratumoral EZH2 expression is a
potent inhibitor of the immune response.
Overview of pharmacologic EZH2 inhibitors
Pharmacologic inhibition of EZH2 has become an active field of research following numerous studies that have
clearly highlighted the pathophysiological implications of PRC2 activation in numerous human malignancies. The
first EZH2 inhibitor with demonstrated antitumor activity was 3-deazaneplanocin A (DZNeP), a drug initially
developed to target the Ebola virus [140]. Mechanistically, DZNeP inhibits the enzyme S-Adenosyl-L-homocysteine
thereby reducing global H3K27me3 levels [141]. Initial studies have shown that DZNeP induces significant apoptotic
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cell death in cancer cells but not in normal cells [142] while effectively targeting subpopulations of cells with stem-like
properties [143]. However, DZNeP carries little clinical value as a drug due to its hydrophilic nature and rapid renal
excretion [144]. Thus, an increasing number of more potent and cell-permeable compounds targeting EZH2 have
been developed and evaluated in clinical trials.
Tazemetostat
To date, Tazemetostat (Tazverik™) is the most extensively studied EZH2 inhibitor in the clinical setting. Notably,
it has received accelerated approval in January 2020 in the USA as frontline therapy for selected cases of epithelioid
sarcoma [145]. It was derived from EPZ005687 following optimization of pharmacokinetic properties [146]. Preclinical
data indicate that Tazemetostat has a 35-fold higher affinity for EZH2 over EZH1 and with Ki value of <2.5 nM
(data from Epizyme). Preclinical studies in cell lines have shown IC50 in the nanomolar range for both wild type
(WT) and mutant EZH2 [147] with marked tumor reduction in xenograft models and concurrent H3K27me3
depletion [148].
In total, 22 clinical trials involving Tazemetostat have been initiated including two Phase III trials that are currently
recruiting patients. In a Phase I study, Tazemetostat demonstrated a favorable safety profile (NCT01897571).
Adverse events were generally of grade 1 and 2 severity and consisted mostly of asthenia (33%), anemia (14%),
anorexia (6%), muscle spasms (14%), nausea (20%) and vomiting (9%) [149]. No deaths were recorded and only
one grade 4 thrombocytopenia occurred. This study established the dose of 800 mg oral administration, twice a day
(PO BID) for completion of Phase II clinical trials involving Tazemetostat. The anticancer activity of Tazemetostat
was evaluated in this study, which showed durable objective responses in 38% of patients with B-cell non-Hodgkin
lymphoma, including some complete responses. However, only 5% of patients with solid tumors exhibited a durable
objective response [149].
In a Phase II trial, Tazemetostat induced responses in 15% of patients with 67% of the responses lasting more
than 6 months [150]. This was a multicenter, double-blind, placebo-controlled, randomized Phase III study leading
to the recent accelerated approval of Tazemetostat in epithelioid sarcoma, thus positioning Tazemetostat as the first
molecularly targeted therapy for this aggressive type of cancer (NCT04204941).
In another Phase Ib clinical trial, Tazemetostat has been investigated in combination with the chemotherapy
regimen R-CHOP in patients with aggressive diffuse large B-Cell lymphoma (DLBCL) [151]. The study consisted
of 17 patients with ages ranging from 60 to 80 years old. Only two dose-limiting toxicities were recorded. In total,
47% of patients experienced grade 3–4 hematologic adverse events. Other commonly observed side effect included
constipation (24%), nausea (12%), as well as hypokalemia (12%). This study also established 800 mg bid as the
recommended Phase II dose [151].
To date, we are still awaiting publicly available results from eight clinical trials involving Tazemetostat. Notably,
there is a completed Phase II trial investigating the use of Tazemetostat in advanced mesothelioma with BAP1 loss
of function (NCT02860286). In addition, another Phase Ib/III is double-blind, randomized, of Tazemetostat or
placebo in combination with Lenalidomide plus Rituximab is recruiting patients diagnosed with recurrent follicular
lymphoma (NCT04224493).
GSK2816126
GSK2816126 is another EZH2 inhibitor that has made its way into clinical testing. It was initially developed in for
the treatment of lymphoma with EZH2-activating mutations. In preclinical studies, GSK2816126 displayed high
selectivity for EZH2 (over 100-fold over EZH1) with Ki ranging in the low nanomolar range for both wild type
and mutant EZH2 and restored the expression of pathologically silenced PRC2 target genes [152]. Furthermore,
GSK2816126 induced cancer cell death in vitro at nanomolar concentrations and displayed significant anti-tumor
activity in xenograft models of EZH2-mutant DLBCL [152].
To date, one clinical trial has investigated GSK2816126. It consisted of an open-label, dose escalation study
aimed at assessing the pharmacodynamics and pharmacodynamics and clinical activity of GSK2816126 in a total
41 patients with either advanced non-Hodgkin’s lymphoma (20) or refractory solid tumors (21) [153]. It was of
a two-part study to determine the recommended Phase II dose (RP2D) for GSK2816126 given biweekly via
intravenous (IV) infusion in a 3-weeks-on/1-week-regimen. The most restricting factor was liver transaminitis,
which limited the maximum-tolerated dose to 2400 mg. All patients had at least one adverse effect with the most
common being nausea and vomiting in about half of patient. Moreover, 32% of patients experienced a significant
complication of grade III or less including pyrexia and fever. With regards to anticancer activity, only one patient
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with lymphoma had a partial radiologic response while 34% of patients achieved stable disease and 51% with
progressive disease [153].
CPI-1205
CPI-1205 is an orally bioavailable, indole-based, small component EZH2 inhibitor that selectively binds to the
EZH2 catalytic pocket [154]. CPI-1205 displays a biochemical IC50 = 0.002 μM a cellular EC50 = 0.032 μM)
for mutant EZH2 [154]. Moreover, CPI-1205 inhibited tumor growth in vitro and in xenograft models of EZH2
mutant DLBCL [154].
These studies paved the way for three clinical trials. The first trial started in 2015 and is currently finished
with results pending. This study was a Phase I sequential dose escalation and expansion study of CPI-1205 in
patients with progressive B-cell lymphomas (NCT02395601). Two other clinical trials involving CPI-1205 are
currently ongoing for which results are currently unavailable. One is ProStar, a Phase Ib/II trial investigating oral
administration of CPI-1205 combined with either enzalutamide or abiraterone/prednisone in metastatic CRPC
(NCT03480646). The second is a Phase I/II trial assessing CPI-1205 + ipilimumab in patients advanced solid
tumors (NCT03525795).
Emerging EZH2 inhibitors
In addition to the compounds discussed above, three more compounds are in clinical trials currently recruiting
patients. CPI-0209 is a second generation EZH2 inhibitor which demonstrated preclinical evidence of anticancer
activity in bladder cancer models (data from Constellation Pharmaceuticals). It will be evaluated taken orally once
daily alone or in combination with Irinotecan in a sequential dose escalation and expansion study in patients with
advanced solid tumors (NCT04104776). Secondly, PF-06821497 is a potent and orally available EZH2 antagonist
currently in Phase I testing for advanced malignancies (NCT03460977). Another orally available EZH2 inhibitor,
SHR2554, is also in a Phase I clinical trial currently recruiting patients with recurrent neoplasms but no preclinical
data could be found in the public domain (NCT03603951).
Considering the recent interest in epigenetic therapies, a number of groups actively continue to develop novel
EZH2 inhibitors. Notably, there are ongoing efforts to optimize pre-existing compounds through rational structure-
activity and drug docking methods to improve pharmacokinetic and pharmacodynamic properties [155]. In addition,
another emerging therapeutic strategy is to design small molecules that disrupt the interaction between EZH2 and
EED, which leads to PRC2 inactivation [156,157]. Thus, the rapid development and success of EZH2-targeted
therapies is likely to continue in the future and will serve as the standard for other epigenetic drug targets.
Combining EZH2 inhibition with immunotherapy: opportunities & challenges
As discussed in the previous paragraphs, EZH2 is a key regulator of cancer immunoediting. In addition, EZH2
inhibitors are being tested in a variety of clinical trials. Hence, it is worth considering the advantages of combining
immunotherapies with clinically available EZH2 inhibitors. Given the pro-oncogenic role of EZH2 and its ability
to suppress both the innate and adaptive immune response, these drug combinations could be highly synergistic.
However, we should consider that EZH2-target genes are tissue- and cancer-specific and that the TME is a diverse
and dynamic assembly of cells interacting with an evolving malignancy. For these reasons, the efficacy and safety
of these combinations should be carefully tested in the context of a specific cancer type and tumor stage. One
should also consider the potential side effects caused by the combination of two treatments that can affect several
physiological systems.
Despite these caveats, emerging evidence indicates that the pharmacological inhibition of EZH2 is a promising
strategy to enhance the efficacy of some clinically available immunotherapies, in particular ICB therapies. While
ICB therapeutic strategies targeting the CTLA-4 and PD-1/PD-L1 axis have revolutionized the management
of melanoma and many solid tumor malignancies, many patients do not respond or develop resistance to these
interventions [158]. In vitro and in vivo experiments on melanoma models have demonstrated the role of EZH2 in
immunotherapy resistance [159,160]. In a melanoma mouse model, anti-CTLA-4 therapy was shown to upregulate
EZH2 expression in melanoma cells, which in turn led to their decreased antigen presentation and immunogenic-
ity. EZH2 inhibitor could reverse these effects, synergize with anti-CTLA-4 and effectively suppress melanoma
growth [159]. Besides cancer cells, anti-CTLA-4 therapy was shown to increase EZH2 expression in peripheral
T cells from treated patients. Pharmacological inhibition of EZH2 in human T cells elicited phenotypic and
functional alterations of the Tregs and enhanced cytotoxic activity of T effectors [160]. Accordingly, anti-CTLA-4
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and EZH2 inhibitor combination therapy in the melanoma-bearing mice significantly reduced tumor growth and
increased mouse survival compared with anti-CTLA-4 monotherapy [160]. In addition to melanoma, an ovarian
cancer preclinical study showed that EZH2 and DNA methyltransferase inhibitors could increase effector T cell
tumor infiltration through upregulating Th1-type chemokines CXCL9 and CXCL10 in TME, hence significantly
augmented the therapeutic efficacy of anti-PD-L1 therapy as well as T cell transfusion therapy [90]. Taken together,
all the above-mentioned immunotherapy resistance is associated with the coordinated silencing of genes involved
in antigen processing, T cell reprograming and cytokine secretion, which can be reversed by EZH2 inhibitors. This
observation suggests that EZH2 targeting drugs could prevent the resistance to a variety of immunotherapies. In
accordance with these findings, other preclinical studies showed that the combination of EZH2 inhibitors and ICBs
is highly synergistic in hepatocellular carcinoma [161] and head and neck cancers [162]. While most of these studies
have tested clinically approved EZH2 inhibitors, one of them employed DZNeP [161], which is the first described
EZH2-targeting drug [143]. Subsequent studies have shown that DZNeP is a global histone methyl-transferase in-
hibitor [141]. Moreover, while DNZeP anticancer activity is greater than that of more specific EZH2 inhibitors [163],
this drug might have a suboptimal pharmacokinetic profile [164]. Hence, the effects of DZNeP cannot be entirely
ascribed to EZH2 inhibition. This example underscores the importance of using clinically available drugs, whose
mechanism of action is fully elucidated, in order to increase the translational significance of preclinical studies.
Based on these results, it would be interesting to test the efficacy of EZH2 inhibitors in combination with ICBs,
particularly in those ICB nonresponsive or resistant cancers. A search on cl inical trials.gov revealed that currently
only two Phase I studies are registered to test this combination. Unfortunately, none of these studies is currently
recruiting patients. It would be interesting to understand why this promising combination is not being investigated
more widely. One potential hindrance is represented by the most common adverse events associated with the use of
ICBs. These events are due to the generalised activation of the immune response and range from a relatively mild
skin rash to the emergence of severe autoimmune diseases (e.g., type I diabetes and myasthenia gravis) [165]. It is
worth noting that the most severe adverse events are relatively rare. However, considering that EZH2 inhibition
has been shown to favor the generalized activation of the adaptive and innate immune system, it is conceivable that
its combination with ICBs could increase the incidence of autoimmune diseases. This potential drawback should
be carefully considered when designing Phase I clinical trials.
Combinations between EZH2 inhibitors and other immunotherapies have been less investigated. However,
recent evidence suggests that EZH2 targeting could be an almost universal strategy to improve the efficacy of
immunotherapies. For example, a study conducted on Ewing sarcoma models showed that EZH2 inhibitors signif-
icantly increased the expression of tumor-associated antigens, thereby improving the effect of CAR-T therapy [166].
CAR-T therapies are being tested in a wide variety of solid and hematological malignancies but are already a feasible
option in diffuse large B-cell lymphomas [167]. Interestingly, EZH2 inhibitors are approved for the treatment of
these lymphomas [168]. Hence, we believe that this combination should be investigated in this disease.
EZH2 inhibitors could also enhance the efficacy of targeted therapies that have also an immunomodulatory
function. For example, it has been shown that EZH2 activates the VEGF-dependent signalling in several cancer
types, thereby promoting angiogenesis and metastasis [169]. Similarly, EZH2 has been implicated in STAT3-
dependent progression of melanoma [170], prostate [171] and bladder cancers [172]. Despite these promising results,
no study has investigated the immunological consequences of combining EZH2 inhibitors with targeted therapies
that inhibit these signalling molecules.
In conclusion, the current evidence strongly suggests that EZH2 inhibitors could improve the efficacy of ICBs in
melanoma and head and neck cancer. The combination with other immunotherapies should be further investigated
in preclinical studies, to assess the best therapeutic strategy and the potential adverse events. In the next section, we
will try to discuss an approach to design these clinical studies within the context of personalized cancer therapy.
Future perspective: personalized epi-immunotherapy
In this review, we have discussed emerging evidence supporting the hypothesis that EZH2 is a main driver of
cancer cells’ immune editing. Interestingly, EZH2 is expressed in cancer cells and in most immune cells that
compose the TME. Hence, EZH2 inhibitors could simultaneously target different components of the malig-
nancy. Despite the promising results of most preclinical studies, several questions need to be addressed before
testing EZH2/immunotherapy combinations in advanced clinical trials. Considering the increasing number of
immunotherapies available and the fact that EZH2 regulates a different set of genes in different tissues, preclinical
trials should be carefully designed to test simultaneously a wide range of treatments, in order to identify the
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best combination for each cancer type (and for each disease stage). In addition, preclinical studies should employ
animal models that mirror as closely as possible the human immune system. This would enable identification of
combinations that are potentially associated with a higher risk of adverse autoimmune events.
One important aspect to consider when designing new EZH2 inhibitor is their toxicological profile. While the
expression patterns of EZH2 have not been fully investigated in all normal human cells, it is generally well accepted
that EZH2 activity remains at a lower level in non-neoplastic cells [173]. For example, a number of publications have
demonstrated that EZH2 levels are highly increased in aggressive cancer cells compared with normal cells [174,175].
Furthermore, EZH2 activity appears to be more important in embryonic development where it plays a role in
proliferation and differentiation [176], thereby making EZH2 less functionally relevant in mature, differentiated cells.
Although generally well tolerated, current EZH2 inhibitors are associated with relevant adverse events, including
liver toxicity and fever. These effects are probably due to the basal expression of EZH2 in normal tissues and to
its relevant functions in the maintenance and specification of different stem cell lineages. Future EZH2-targeting
drugs should be designed to specifically penetrate cancer cells and/or to be administered selectively in the neoplastic
tissue.
When an optimal and safe combination is identified, the clinical trial design should consider the wide variety
of molecular alterations observed in human malignancies. Next generation sequencing data from different cohorts
have extensively demonstrated that most cancer types are characterized by an elevated degree of intratumoral and
intertumoral heterogeneity [177]. Given the complex and dynamic relationship between the TME and the malignant
cells, it will be important to develop personalized diagnostic tools that aim to: identify the patients more likely
to benefit from the EZH2/immunotherapy combination; follow-up the therapeutic response. We believe that the
best approach to obtain these goals is to design clinical trials aimed at identifying biomarkers that predict the
response to both immunotherapy and EZH2-targeting drugs. The markers of response to immunotherapy will
be different, depending on the specific therapeutic strategy. For example, it has been shown that the mutational
burden of cancers is a good indicator of response to ICBs [178]. As expected, circulating biomarkers of angiogenesis
have been identified as better predictors of response to therapies that inhibit VEGF-dependent pathways [179].
In any case, it will be important to identify minimally invasive diagnostic tools, such as those that allow the
measurement of biomarkers from blood, urine and other biological fluids. This strategy will enable the clinicians to
reassess the patient’s response to the combination periodically and to modify the therapeutic regimen accordingly.
Interestingly, the tumor mutational burden can be estimated by techniques that enable the sequencing of circulating
tumor DNA [180]. At present, there is no validated method to measure intratumoral EZH2 activity noninvasively.
However, we believe that a recently developed technique could be modified for this purpose.
Cell free (cf ) circulating nucleosomes have been recognized as novel, noninvasive biomarkers in oncology.
Increased levels of nucleosomes in circulation have been associated both with tumor burden and progression
in multiple cancers [181,182]. Nucleosomes and their associated DNA can be released upon apoptotic cell death
and associated chromatin fragmentation [183] as well as necrotic cell death and degradation of larger chromatin
fragments [184]. The histone content of the nucleosome protects the associated DNA from circulating DNase activity
resulting in a peak size of around 167 bp.
While detection of total cf nucleosomes has been possible for some time [185] recently developed innovative
immunoassays have enabled detection and genome wide profiling of cf nucleosomes containing histone and
DNA modifications as well as histone variants associated with tumor-specific epigenetic changes, not only at the
tumor site, but also noninvasively in the circulation in an approach referred to as Nucleosomics™ [186,187]. Using this
technology, cancer associated epigenetic changes of cf nucleosomes have been identified as putative diagnostic panels
for pancreatic cancer [188] and colorectal cancer [189] as well as lung disease [190] using serum samples. Circulating
H3K27me3 has been measured in serum using a first generation qualitative Nu.Q™ assay [188]. Our recent in
vitro data [Unpublished data] developed with a prototype second generation quantitative Nu.Q H3K27me3 assay,
shows the feasibility of monitoring cellular EZH2 activity in cell extracts and supernatants. Nu.Q research use
assays consist of epitope specific antibodies coated in a 96-well plate format with an anti-nucleosome detection
antibody. Nucleosomes are detected using a colorimetric readout. Analytically validated kits are now commercially
available and a pipeline of additional kits is in development for research use and in clinical format. The kits include
a recombinant nucleosome standard to allow quantitative assessment of specific nucleosome levels. This strongly
supports the utility of using the Nu.Q H3K27me3 assay to quantify the effects of EZH2 activity in tumor derived
cf circulating nucleosomes.
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Figure 4. A strategy for personalized epi-immunotherapy. Using a liquid biopsy approach (e.g., from a blood
sample) relevant information about cancer-specific mutations and epigenetic alterations (H3K27me3) levels can be
obtained. The first information will enable clinicians to select the optimal immunotherapy, while the latter is useful
to identify cancers with higher EZH2 activity and therefore more sensitive to EZH2 inhibitors. The same approach can
be employed for dynamic monitoring of cancer progression during the therapy.
We believe that the Nu.Q assay approach, in combination with a pharmacogenetic assay for immunotherapy
would enable clinicians to select the best EZH2-immunotherapy combination and to follow-up the response to
both drugs (Figure 4). Given the broad range of immuno-activating functions displayed by EZH2 inhibitors, we
think several of these combinations will improve the survival of patients with different cancers.
Executive summary
• Immunotherapies are emerging as an effective treatment for incurable malignancies. However, some patients
display acquired or intrinsic resistance to these treatments.
• In addition to genetic mutations, epigenetic alterations are emerging as key mechanisms of resistance to cancer
immunotherapies. Notably, epigenetic modifications are reversible and can be targeted by clinically approved
drugs.
• EZH2 is an epigenetic mediator that induces epigenetic gene silencing via histones post translational
modifications. EZH2 can also methylate other proteins (e.g., transcription factors) that in turn control gene
expression.
• EZH2 is overexpressed in many solid tumors and associated with worse prognosis. Higher EZH2 expression in
cancer cells and in the tumor microenvironment suppresses the adaptive and innate immune response.
• EZH2 inhibition is a promising strategy to improve the efficacy of cancer immunotherapies and to prevent the
occurrence of resistance.
• Three EZH2 inhibitors have entered clinical trials for the treatment of human malignancies. These inhibitors are
generally well tolerated and have shown some anticancer activity.
• A recently developed technology enables the measurement of EZH2 activity in patients’ blood samples. We
envisage that this technology could be coupled with the use of EZH2 inhibitors and with DNA-based liquid
biopsies to develop personalized epi-immunotherapies.
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